H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 13 from EUR 10 and keeps a Buy rating on the shares. The company announced positive results from the melanoma patient subset of cohort 3 of the ongoing Phase 1 Study 1100 evaluating JNJ-1900, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix price target raised to $14 from $9 at Leerink
- Nanobiotix Reveals Promising Phase 1 Results for Melanoma Treatment
- Nanobiotix announces new results from JNJ-1900 study
- Nanobiotix Updates Voting Rights and Share Capital Information
- Nanobiotix to Present at H.C. Wainwright Investment Conference